HRP20192278T1 - Derivati 8-hidroksi-kinolina - Google Patents
Derivati 8-hidroksi-kinolina Download PDFInfo
- Publication number
- HRP20192278T1 HRP20192278T1 HRP20192278TT HRP20192278T HRP20192278T1 HR P20192278 T1 HRP20192278 T1 HR P20192278T1 HR P20192278T T HRP20192278T T HR P20192278TT HR P20192278 T HRP20192278 T HR P20192278T HR P20192278 T1 HRP20192278 T1 HR P20192278T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- groups
- branched
- carbon atoms
- lower alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1000243A HUP1000243A2 (en) | 2010-05-06 | 2010-05-06 | 8-hidroxy-quinoline derivatives |
| EP11752335.7A EP2566849B1 (en) | 2010-05-06 | 2011-05-06 | 8-hydroxy-quinoline derivatives |
| PCT/HU2011/000043 WO2011148208A1 (en) | 2010-05-06 | 2011-05-06 | 8-hydroxy-quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192278T1 true HRP20192278T1 (hr) | 2020-03-06 |
Family
ID=89989711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192278TT HRP20192278T1 (hr) | 2010-05-06 | 2011-05-06 | Derivati 8-hidroksi-kinolina |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8871937B2 (enExample) |
| EP (1) | EP2566849B1 (enExample) |
| JP (1) | JP5812541B2 (enExample) |
| KR (1) | KR101837974B1 (enExample) |
| CN (1) | CN102985407B (enExample) |
| AU (1) | AU2011256989B2 (enExample) |
| CA (1) | CA2798419C (enExample) |
| CY (1) | CY1122426T1 (enExample) |
| DK (1) | DK2566849T3 (enExample) |
| EA (1) | EA021026B1 (enExample) |
| ES (1) | ES2761832T3 (enExample) |
| HR (1) | HRP20192278T1 (enExample) |
| HU (2) | HUP1000243A2 (enExample) |
| MX (1) | MX337999B (enExample) |
| NZ (1) | NZ603967A (enExample) |
| PL (1) | PL2566849T3 (enExample) |
| PT (1) | PT2566849T (enExample) |
| RS (1) | RS59678B1 (enExample) |
| SI (1) | SI2566849T1 (enExample) |
| SM (1) | SMT201900710T1 (enExample) |
| WO (1) | WO2011148208A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP1500098A2 (hu) | 2015-03-09 | 2016-09-28 | Avidin Kft | 8-hidroxikinolin származékok új enantiomerjei és szintézisük |
| US10624881B2 (en) * | 2015-10-12 | 2020-04-21 | Health Research, Inc. | Methods for inducing apoptosis in cancer cells |
| CN105367553A (zh) * | 2015-12-04 | 2016-03-02 | 广东工业大学 | 一种他克林-8-羟（胺）基喹啉衍生物及其应用 |
| HUP1600234A2 (en) | 2016-04-05 | 2017-12-28 | Mta Termeszettudomanyi Kutatokoezpont | Mdr-reversing 8-hydroxy-quinoline derivatives |
| WO2024073624A2 (en) * | 2022-09-28 | 2024-04-04 | The Research Foundation For The State University Of New York | Antiproliferative betti bases and prodrugs thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544972B1 (en) | 1997-09-25 | 2003-04-08 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| AU2474399A (en) | 1998-01-26 | 1999-08-09 | Mitokor | Mitochondria protecting agents for treating mitochondria associated diseases |
| US6737511B1 (en) | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| CN1235875C (zh) | 1999-08-27 | 2006-01-11 | 西托维亚公司 | 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
| US6890896B1 (en) | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| GB0011095D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | astrin and cholecystokinin receptor ligands (III) |
| WO2002030411A2 (en) | 2000-10-13 | 2002-04-18 | Johns Hopkins University | Treatment of apoptotic cell death |
| AU2002239595A1 (en) | 2000-12-15 | 2002-06-24 | Mitokor | Compounds for altering mitochondrial function and cellular responses |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| CN1526011A (zh) | 2001-07-10 | 2004-09-01 | IDECҩ�﹫˾ | 抑制凋亡过程及改善细胞性能 |
| DE10144153A1 (de) | 2001-09-07 | 2003-03-27 | Newfrey Llc | Halteclip mit versetzten Rastfingern |
| CA2475963A1 (en) | 2002-02-13 | 2003-09-04 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating vascular disease |
| BRPI0407757A (pt) | 2003-02-28 | 2006-02-14 | Inotek Pharmaceuticals Corp | derivados de benzamida tetracìclica e métodos de uso dos mesmos |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| JP4824566B2 (ja) | 2003-05-28 | 2011-11-30 | エーザイ インコーポレーテッド | Ｐａｒｐを阻害するための化合物、方法、および医薬組成物 |
| CA2554166C (en) | 2004-01-23 | 2014-07-29 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| CN101309908A (zh) | 2005-11-15 | 2008-11-19 | 艾博特公司 | 作为有效parp抑制剂的取代的1h-苯并咪唑-4-甲酰胺化合物 |
| US7528174B2 (en) | 2006-01-06 | 2009-05-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Selective targeting agents for mitochondria |
| CN101611009A (zh) * | 2006-07-25 | 2009-12-23 | 伊维沃制药股份有限公司 | 喹啉衍生物 |
| US8609649B2 (en) * | 2007-03-20 | 2013-12-17 | Brandeis University | Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases |
| US8183236B2 (en) * | 2007-04-12 | 2012-05-22 | University Of Southern California | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics |
| WO2008153760A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| WO2009151972A1 (en) * | 2008-05-28 | 2009-12-17 | , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command | Small molecule inhibitors of botulinum neurotoxins |
| US8658170B2 (en) * | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
| US8618302B2 (en) * | 2010-01-06 | 2013-12-31 | Joseph P. Errico | Methods and compositions of targeted drug development |
-
2010
- 2010-05-06 HU HU1000243A patent/HUP1000243A2/hu unknown
-
2011
- 2011-05-06 EP EP11752335.7A patent/EP2566849B1/en active Active
- 2011-05-06 RS RS20191622A patent/RS59678B1/sr unknown
- 2011-05-06 WO PCT/HU2011/000043 patent/WO2011148208A1/en not_active Ceased
- 2011-05-06 SM SM20190710T patent/SMT201900710T1/it unknown
- 2011-05-06 EA EA201270787A patent/EA021026B1/ru unknown
- 2011-05-06 KR KR1020127030702A patent/KR101837974B1/ko active Active
- 2011-05-06 NZ NZ603967A patent/NZ603967A/en not_active IP Right Cessation
- 2011-05-06 PL PL11752335T patent/PL2566849T3/pl unknown
- 2011-05-06 US US13/696,541 patent/US8871937B2/en active Active
- 2011-05-06 CA CA2798419A patent/CA2798419C/en active Active
- 2011-05-06 PT PT117523357T patent/PT2566849T/pt unknown
- 2011-05-06 HR HRP20192278TT patent/HRP20192278T1/hr unknown
- 2011-05-06 DK DK11752335.7T patent/DK2566849T3/da active
- 2011-05-06 JP JP2013508559A patent/JP5812541B2/ja active Active
- 2011-05-06 HU HUE11752335A patent/HUE050886T2/hu unknown
- 2011-05-06 CN CN201180033524.5A patent/CN102985407B/zh active Active
- 2011-05-06 ES ES11752335T patent/ES2761832T3/es active Active
- 2011-05-06 SI SI201131826T patent/SI2566849T1/sl unknown
- 2011-05-06 MX MX2012012883A patent/MX337999B/es active IP Right Grant
- 2011-05-06 AU AU2011256989A patent/AU2011256989B2/en not_active Ceased
-
2019
- 2019-12-17 CY CY20191101327T patent/CY1122426T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011256989B2 (en) | 2014-08-21 |
| PT2566849T (pt) | 2020-01-06 |
| EA021026B1 (ru) | 2015-03-31 |
| HUE050886T2 (hu) | 2021-01-28 |
| EA201270787A1 (ru) | 2013-04-30 |
| CA2798419A1 (en) | 2011-12-01 |
| CN102985407A (zh) | 2013-03-20 |
| US8871937B2 (en) | 2014-10-28 |
| KR20130029772A (ko) | 2013-03-25 |
| CA2798419C (en) | 2021-01-05 |
| JP5812541B2 (ja) | 2015-11-17 |
| MX337999B (es) | 2016-03-30 |
| AU2011256989A1 (en) | 2013-01-10 |
| SMT201900710T1 (it) | 2020-01-14 |
| HU1000243D0 (en) | 2010-06-28 |
| KR101837974B1 (ko) | 2018-03-13 |
| EP2566849B1 (en) | 2019-09-18 |
| HUP1000243A2 (en) | 2012-01-30 |
| EP2566849A1 (en) | 2013-03-13 |
| JP2013525473A (ja) | 2013-06-20 |
| ES2761832T3 (es) | 2020-05-21 |
| MX2012012883A (es) | 2013-03-20 |
| PL2566849T3 (pl) | 2020-03-31 |
| SI2566849T1 (sl) | 2020-02-28 |
| US20130131096A1 (en) | 2013-05-23 |
| RS59678B1 (sr) | 2020-01-31 |
| CN102985407B (zh) | 2015-09-09 |
| CY1122426T1 (el) | 2021-01-27 |
| NZ603967A (en) | 2014-06-27 |
| WO2011148208A1 (en) | 2011-12-01 |
| DK2566849T3 (da) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015004529A2 (pt) | alcóxi pirazóis como ativadores de guanilato ciclase solúvel | |
| HRP20192278T1 (hr) | Derivati 8-hidroksi-kinolina | |
| MX384426B (es) | Proceso para preparar derivados de fenil sulfamoilpirrolamidas | |
| ME03757B (me) | Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti | |
| BR112015009395A2 (pt) | processo para preparação de derivados do ácido biliar | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| BR112017000943A2 (pt) | ácidos carboxílicos heterocíclicos como ativadores de guanilato ciclase solúveis | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| ME02861B (me) | Postupak za pripremu treprostinila i njegovih derivata | |
| MX2014015501A (es) | Carboxamidas heterociclicas fungicidas. | |
| MY171627A (en) | Stripping and cleaning compositions for removal of thick film resist | |
| IN2014MN01839A (enExample) | ||
| MX373711B (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CU20160030A7 (es) | Compuestos éteres de arilo yútiles para tratar cancer de célula renal | |
| MY185233A (en) | Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds as notch inhibitors | |
| MX383762B (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
| AR091857A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| BR112014030743A2 (pt) | inibidores de neprilisina | |
| MX379205B (es) | Derivados de bisamida del ácido dicarboxilico, uso de los mismos. composición farmacéutica a base de los mismos, y métodos para producir derivados de bisamida del ácido dicarboxílico. | |
| JP2016529319A5 (enExample) | ||
| ME02834B (me) | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamid i n-(4-hidroksi-4-metilcikloheksil)- 4-(2-piridil)benzensulfonamid i nihova terapijska upotreba | |
| MX2018014164A (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico. | |
| BR112015029504A2 (pt) | inibidores quinase | |
| BR112015017740A2 (pt) | composto heterocíclico condensado | |
| ME01595B (me) | Benzamidinska jedinjenja koja su korisna kao inhibitori histonske deacetilaze |